Monoclonal Anti- Polycomb complex protein BMI-1 Antibody
Size: 100 μg
Host: Mouse
Reactivity: Human, mouse, rat
Isotype: IgG2a
Application: WB, IHC-P, ICC, Flow-Cyt
--------------------------------------------------------------------------------------------------------------
Price: $180.00
Catalog# BMA1036
Lot # Check on the product label
Size 100 μg
Isotype IgG2a
Clone # P9
Host Mouse
Reactivity Human, mouse, rat
Product Form Liquid
Purification Protein A purified
Immunogen
Recombinant protein within human Bmi1 full sequence.
Recommend Application
Western Blot, WB (1:500)
Immunohistochemistry, IHC-P (1:100)
Immunocytochemistry, ICC (1:100)
Flow Cytometry, Flow-Cyt (1:50-1:100)
Other applications have not been tested.
The optimal dilutions should be determined by end user.
Storage Buffer
1*PBS (pH7.4), 0.2% BSA, 40% Glycerol and 0.05% Sodium Azide.
Storage Instruction
Store at 4°C after thawing (1 week). Aliquot and store at -20°C for long term (at least one year).
Avoid repeated freeze and thaw cycles.
Background
BMI1 has been reported as an oncogene by regulating p16 and p19, which are cell cycle inhibitor genes. BMI1 knockout in mice results in defects in hematopoiesis, skeletal patterning, neurological functions, and development of the cerebellum. It is a component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development. BMI1 is necessary for efficient self-renewing cell divisions of adult hematopoietic stem cells as well as adult peripheral and central nervous system neural stem cells. BMI1 is also thought to inhibit ageing in neurons through the suppression of p53.
Reference
1. Buchwald G., van der Stoop P., Weichenrieder O., Perrakis A., van Lohuizen M., Sixma T.K. "Structure and E3-ligase activity of the Ring-Ring complex of polycomb proteins Bmi1 and Ring1b." EMBO J. 25:2465-2474(2006)
2. Park IK, Morrison SJ, Clarke MF (January 2004). "Bmi1, stem cells, and senescence regulation". J. Clin. Invest. 113 (2): 175–9.
3. Chatoo W, Abdouh M, David J, Champagne MP, Ferreira J, Rodier F, Bernier G (2009).